Streetbeat News

HLN

Haleon plc

https://www.haleon.com

Industry

Drug Manufacturers - Specialty & Generic

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

Open

9.83

Mkt cap

44B

Volume

10M

High

9.84

P/E Ratio

28.71

52-wk high

10.80

Low

9.71

Div yield

0.02

52-wk low

7.89

Haleon plc is experiencing strong organic growth driven by its oral health brands, despite challenging comparisons in the VMS segment. The company maintains its guidance for 4-6% organic growth, excluding FX effects, despite Q3 momentum.

Portfolio Pulse from

December 10, 2024 | 11:30 pm

Haleon has appointed Joe Sta-Romana as Chief Customer Officer for its US business, effective December 1, 2024, to lead growth and transformation.

Portfolio Pulse from

December 02, 2024 | 1:00 pm

Kenvue Inc. (NYSE:KVUE) shares rose on Monday after reports that activist investor Starboard Value acquired a significant stake in the company, aiming to boost its stock price. Starboard may push for the sale of Kenvue's skin, healthcare, and beauty division. Kenvue's stock has underperformed compared to competitors like Haleon and Proctor & Gamble.

Portfolio Pulse from Dylan Berman

October 21, 2024 | 5:54 pm

Sanofi is negotiating with Clayton Dubilier & Rice to sell a 50% stake in its consumer healthcare unit, Opella, for approximately $16.4 billion. This move aligns with Sanofi's strategy to focus on innovative medicines and vaccines. Goldman Sachs and Morgan Stanley are preparing debt financing for potential buyers.

Portfolio Pulse from Vandana Singh

October 11, 2024 | 12:57 pm

Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding from 22.6% to 15%. Despite the sale, Pfizer remains Haleon's largest shareholder. This move follows Pfizer's recent challenges, including the withdrawal of its sickle cell treatment Oxbryta. Pfizer's stock showed a slight pre-market gain, while Haleon's stock has risen significantly this year.

Portfolio Pulse from Kaustubh Bagalkote

October 01, 2024 | 10:25 am

Pfizer has increased its offering size of Haleon shares from 540 million to 640 million, as reported by Bloomberg.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 6:08 pm

Pfizer plans to sell approximately 540 million ordinary shares in Haleon Plc, as reported by Reuters citing a bookrunner.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 3:58 pm

Sanofi plans to spin off its consumer healthcare business to focus on drug development and cost-cutting. Private equity firms are interested, and the unit could be valued at over $20 billion. Goldman Sachs and Morgan Stanley are preparing financing for potential buyers.

Portfolio Pulse from Vandana Singh

September 25, 2024 | 11:18 am

Morgan Stanley analyst Rashad Kawan maintains an Overweight rating on Haleon (NYSE:HLN) and raises the price target from $9.9 to $10.95.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 12:05 pm

PubMatic has partnered with Haleon to optimize video and CTV ads globally, enhancing supply path transparency and sustainability. This collaboration aims to improve efficiency and performance for Haleon's brands like Advil, Centrum, and Tums.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:02 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.